D81.39 Other adenosine deaminase deficiency

Name of the Condition

• Other adenosine deaminase deficiency

Summary

Other adenosine deaminase (ADA) deficiency is a rare inherited disorder that impairs the immune system, leading to severe combined immunodeficiency (SCID). This condition results from genetic mutations that reduce or eliminate the activity of the ADA enzyme, disrupting the development and function of lymphocytes (T cells, B cells, and natural killer cells). The deficiency causes a buildup of toxic metabolites, which damage immune cells and impair the body's ability to fight infections. Without treatment, ADA deficiency is typically fatal in early childhood due to recurrent, severe infections.

Causes

ADA deficiency is caused by genetic mutations in the ADA gene, which provides instructions for producing the adenosine deaminase enzyme. These mutations disrupt the enzyme's function, leading to the accumulation of toxic substances that destroy lymphocytes. The condition is inherited in an autosomal recessive pattern, meaning an individual must inherit two mutated copies of the gene (one from each parent) to develop the disorder. Carriers (those with one mutated copy) typically do not show symptoms.

Risk Factors

• Genetic predisposition, often with a family history of immunodeficiency disorders.
• Consanguinity (parents who are closely related) increasing the risk of autosomal recessive forms.

Symptoms

• Recurrent, severe infections (e.g., pneumonia, sepsis, thrush).
• Failure to thrive or poor growth.
• Chronic diarrhea.
• Skin rashes or eczema.
• Persistent oral candidiasis.
• Enlarged lymph nodes or spleen.

Diagnosis

Diagnosis involves clinical evaluation of immunodeficiency symptoms, followed by laboratory tests. These may include measuring ADA enzyme activity in red blood cells or white blood cells, genetic testing for ADA gene mutations, and assessing lymphocyte counts and function. Newborn screening for SCID may also detect ADA deficiency early.

Treatment Options

• Enzyme replacement therapy (e.g., pegademase bovine).
• Hematopoietic stem cell transplantation (HSCT) to restore immune function.
• Gene therapy (experimental in some cases).
• Prophylactic antibiotics, antifungals, or antivirals to prevent infections.
• Immunoglobulin replacement therapy.

Prognosis and Follow-Up

With early diagnosis and treatment, prognosis improves significantly. Enzyme replacement and HSCT can restore immune function, allowing survival into adulthood. Lifelong monitoring for infections, immune reconstitution, and treatment-related complications is essential. Regular follow-up with immunology specialists is recommended.

Complications

• Recurrent life-threatening infections.
• Graft-versus-host disease (post-transplant).
• Side effects from enzyme replacement or immunosuppressive therapy.
• Developmental delays due to chronic illness.
• Increased risk of certain cancers (e.g., lymphoma) in untreated cases.

Lifestyle & Prevention

• Strict infection control (e.g., avoiding sick contacts, hygiene practices).
• Vaccination schedules tailored to immune status (live vaccines are contraindicated).
• Nutritional support to address failure to thrive.
• Genetic counseling for families with a history of ADA deficiency.

When to Seek Professional Help

Seek immediate medical attention for:

• Fever or signs of infection (e.g., difficulty breathing, lethargy).
• Unexplained weight loss or poor feeding in infants.
• Persistent or worsening skin rashes or oral thrush.
• Recurrent infections despite treatment.

Tips for Medical Coders

Document the specific subtype of ADA deficiency (e.g., partial vs. complete) and any associated complications (e.g., infections, transplant status) to support accurate coding. Ensure clinical documentation aligns with the ICD-10-CM code D81.39, which is used for other specified forms of ADA deficiency not classified elsewhere. Verify that the diagnosis is clearly differentiated from unspecified or severe combined immunodeficiency variants.